Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?

Pancreatic cancer, although not very frequent, has an exceptionally high mortality rate, making it one of the most common causes of cancer mortality in developed countries. Pancreatic cancer is difficult to diagnose, allowing few patients to have the necessary treatment at a relatively early stage....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	World journal of gastroenterology : WJG 2013-02, Vol.19 (8), p.1173-1181
Hauptverfasser:	Koutsounas, Ioannis, Giaginis, Constantinos, Theocharis, Stamatios
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Clinical Trials as Topic Evidence-Based Medicine Histone Deacetylase Inhibitors - adverse effects Histone Deacetylase Inhibitors - therapeutic use Histone Deacetylases - metabolism Humans Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - enzymology Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Review Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!